Pfizer's CEO warns that China's meticulously executed national plan for pharma—improving regulators, strengthening IP, and funding science—is a disruptive force. Operating at half the cost and three times the speed, China is on track to lead in multiple areas of drug discovery within 1-2 years.

Jeremy Levin outlines China's deliberate, 25-year strategic plan for biotech, moving from API production to CROs, attracting scientific talent, creating lookalikes, and now developing novel medicines. He warns that unless the U.S. treats biotech as a strategic asset, China's state-driven approach will make it the dominant innovator within five years, partly funded by Western pharma investments.

China rapidly overtook established players by executing a national strategy for pharma innovation. They built a comprehensive ecosystem that includes attracting top overseas talent with incentives, providing state-backed venture capital, massively funding university research, and creating a large home market for innovative drugs.

Through massive government investment in biotech infrastructure, China has become the global hub for early-stage clinical drug development. Both Chinese and Western companies now conduct initial human trials there to move much faster and at a significantly lower cost, giving China a strategic foothold in the pharma value chain.

China is no longer just a low-cost manufacturing hub for biotech. It has become an innovation leader, leveraging regulatory advantages like investigator-initiated trials to gain a significant speed advantage in cutting-edge areas like cell and gene therapy. This shifts the competitive landscape from cost to a race for speed and novel science.

Beyond sheer scale, China's innovation leads in complex, next-generation drug modalities like ADCs and bispecifics. Chinese biotechs now account for roughly one-third of the global Phase 1 and 2 pipelines for these advanced therapies, indicating a shift from iteration on established targets to leadership in new technology platforms.

Driven by significant government investment, China is rapidly becoming a leader in biotech R&D, licensing, and outsourcing. This shift is a top-of-mind concern for US biotech and pharma executives, with China now involved in a majority of top R&D licensing deals.

China's rise in biotech isn't just about cost. It's driven by a tightly integrated ecosystem where drug designers and wet lab technicians work closely, creating a much faster feedback loop than the siloed, outsourced model common in the US.

China is poised to become the next leader in biotechnology due to a combination of structural advantages. Their regulatory environment is moving faster, they have a deep talent pool, and they can conduct clinical trials at a greater speed and volume than the U.S., giving them a significant edge.